CNSI Cambridge Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Green Receipt who wrote (516)	7/23/1999 10:13:00 AM
From: Mike McFarland	Read Replies (1) of 675

Second Quarter 1999 Financial Results biz.yahoo.com (snip) The increase in revenue was attributable to research reimbursements by Bayer AG of costs incurred by the Company under its GGF collaboration. The Company's cash balance as of June 30, 1999 was $10.8 million, a decrease of $1.1 million since December 31, 1998. ''By continuing to focus resources on our two externally-funded programs, we have been able to effectively manage expenditures,'' said Harry Wilcox, Chief Executive Officer of the Company. ''We continue to be pleased with the progress of our collaborations with Allergan for ophthalmic disorders and Bayer for multiple sclerosis and other neuropathies.'' ____ lean and mean, cnsi is a damn good value-- ...it may be several more years however David-- just be ready to do a quick trade if they file INDs and something gets out into the press about it.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next